Apoptosis, Bcl-2, and proliferating cell nuclear antigen in the failing human heart: observations made after implantation of left ventricular assist device.

[1]  T. Aoyama,et al.  Significance of myocytes with positive DNA in situ nick end-labeling (TUNEL) in hearts with dilated cardiomyopathy: not apoptosis but DNA repair. , 1999, Circulation.

[2]  E. Yeh,et al.  Life and death in the cardiovascular system. , 1997, Circulation.

[3]  R. Virmani,et al.  Apoptosis in myocytes in end-stage heart failure. , 1996, The New England journal of medicine.

[4]  L. Kirshenbaum,et al.  The bcl-2 gene product prevents programmed cell death of ventricular myocytes. , 1997, Circulation.

[5]  E. Sonnenblick,et al.  Stretch-induced programmed myocyte cell death. , 1995, The Journal of clinical investigation.

[6]  M. Oz,et al.  Selection criteria for placement of left ventricular assist devices. , 1995, American heart journal.

[7]  C. Thompson,et al.  Apoptosis in the pathogenesis and treatment of disease , 1995, Science.

[8]  A. Wyllie.  Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation , 1980, Nature.

[9]  G. D. De Meyer,et al.  RNA synthesis and splicing interferes with DNA in situ end labeling techniques used to detect apoptosis. , 1998, The American journal of pathology.

[10]  Y. Hayakawa,et al.  Expression of bcl-2 protein, an inhibitor of apoptosis, and Bax, an accelerator of apoptosis, in ventricular myocytes of human hearts with myocardial infarction. , 1996, Circulation.

[11]  S. Hetts.  To die or not to die: an overview of apoptosis and its role in disease. , 1998, JAMA.

[12]  H Harasaki,et al.  Left ventricular echocardiographic and histologic changes: impact of chronic unloading by an implantable ventricular assist device. , 1996, Journal of the American College of Cardiology.

[13]  C A Beltrami,et al.  Structural basis of end-stage failure in ischemic cardiomyopathy in humans. , 1994, Circulation.

[14]  R. S. Williams,et al.  Apoptosis and heart failure. , 1999, The New England journal of medicine.

[15]  Guido Kroemer,et al.  The proto-oncogene Bcl-2 and its role in regulating apoptosis , 1997, Nature Medicine.

[16]  W. Bursch,et al.  Cell death by apoptosis and its protective role against disease. , 1992, Trends in pharmacological sciences.

[17]  E. Lakatta,et al.  Increased cardiomyocyte apoptosis during the transition to heart failure in the spontaneously hypertensive rat. , 1997, The American journal of physiology.

[18]  R. Osamura,et al.  Apoptotic cells in the human endometrium and placental villi: pitfalls in applying the TUNEL method. , 1995, Archives of histology and cytology.

[19]  David L. Vaux,et al.  An evolutionary perspective on apoptosis , 1994, Cell.

[20]  G Olivetti,et al.  Cardiomyopathy of the aging human heart. Myocyte loss and reactive cellular hypertrophy. , 1991, Circulation research.

[21]  E. Sonnenblick,et al.  The cellular basis of dilated cardiomyopathy in humans. , 1995, Journal of molecular and cellular cardiology.

[22]  C A Beltrami,et al.  Apoptosis in the failing human heart. , 1997, The New England journal of medicine.

[23]  A. Wyllie,et al.  Apoptosis: A Basic Biological Phenomenon with Wide-ranging Implications in Tissue Kinetics , 1972, British Journal of Cancer.

[24]  T. N. James,et al.  Normal and abnormal consequences of apoptosis in the human heart: from postnatal morphogenesis to paroxysmal arrhythmias. , 1994, Transactions of the American Clinical and Climatological Association.

[25]  M C Oz,et al.  Reversal of chronic ventricular dilation in patients with end-stage cardiomyopathy by prolonged mechanical unloading. , 1995, Circulation.